Clinical Trials Logo

Pediatric ALL, B Cell clinical trials

View clinical trials related to Pediatric ALL, B Cell.

Filter by:
  • None
  • Page 1

NCT ID: NCT04604691 Recruiting - Clinical trials for Minimal Residual Disease

Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)

Start date: February 18, 2022
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, multi-center phase I study using blinatumomab for pediatric B-cell acute lymphoblastic leukemia patients with positive of minimal residual disease. 1 Cycle of blinatumomab treatment followed by hematopoietic stem cell transplantation. Blinatumomab has approved to treat adults and children with B-cell precursor ALL who are in remission but still have MRD. However, data on the effects and safety of blinatumomab in children with B-precursor ALL with MRD positive are insufficient.